Adamas Reports Recent Achievements and Financial Results for the Fourth Quarter and Full-Year 2017
February 22, 2018 16:01 ET
|
Adamas Pharmaceuticals, Inc.
EMERYVILLE, Calif., Feb. 22, 2018 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today reported recent achievements and financial results for the fourth quarter and full-year ended...
Adamas Announces U.S. Commercial Launch of GOCOVRI™ the First and Only FDA-approved Medication for the Treatment of Dyskinesia in Parkinson’s Disease Patients
January 08, 2018 16:41 ET
|
Adamas Pharmaceuticals, Inc.
EMERYVILLE, Calif., Jan. 08, 2018 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced the full commercial launch of its flagship product, GOCOVRI™ (amantadine) extended...
Adamas Reports Recent Achievements and Third Quarter 2017 Financial Results
November 02, 2017 16:01 ET
|
Adamas Pharmaceuticals, Inc.
EMERYVILLE, Calif., Nov. 02, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today reported recent achievements and financial results for the third quarter ended September 30,...
Adamas to Host Investor and Analyst Meeting on September 18, 2017
September 13, 2017 16:53 ET
|
Adamas Pharmaceuticals, Inc.
EMERYVILLE, Calif., Sept. 13, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that it will host an Investor and Analyst meeting on Monday, September 18, 2017 from...
Adamas Announces FDA Approval of GOCOVRI™ as First and Only Medication for the Treatment of Dyskinesia in Parkinson’s Disease Patients
August 24, 2017 16:16 ET
|
Adamas Pharmaceuticals, Inc.
EMERYVILLE, Calif., Aug. 24, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that the U.S. Food and Drug Administration (FDA) has approved GOCOVRI (amantadine)...
Adamas Reports Recent Achievements and Second Quarter 2017 Financial Results
August 08, 2017 16:01 ET
|
Adamas Pharmaceuticals, Inc.
EMERYVILLE, Calif., Aug. 08, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today reported recent achievements and financial results for the second quarter ended June 30, 2017. ...
Adamas to Announce First Quarter 2017 Financial Results and Host Conference Call on May 9, 2017
May 02, 2017 16:06 ET
|
Adamas Pharmaceuticals, Inc.
EMERYVILLE, Calif., May 02, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that the company will report first quarter 2017 financial results on Tuesday, May 9,...
Adamas Presents ADS-5102 Pooled Phase 3 Data Confirming Statistically Significant Reduction in Levodopa-Induced Dyskinesia and OFF Time in People with Parkinson’s Disease
April 24, 2017 09:06 ET
|
Adamas Pharmaceuticals, Inc.
-- Results presented in oral platform and poster sessions at the 69th American Academy of Neurology (AAN) Annual Meeting -- -- Results from the pooled analysis showed approximately twice as many...
Adamas Announces Oral and Poster Presentations of ADS-5102 Pooled Phase 3 Data at the 69th American Academy of Neurology Annual Meeting
April 18, 2017 12:07 ET
|
Adamas Pharmaceuticals, Inc.
EMERYVILLE, Calif., April 18, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced details regarding upcoming oral platform and poster presentations highlighting...